The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesise that carnosine supplementation will improve:
1. glycaemic control
2. cardiovascular risk factors
3. cognitive outcomes
in patients with prediabetes and type 2 diabetes, and this will be modulated by reduction in
chronic low grade inflammation, oxidative stress and circulating advanced glycation end
products levels.
3. Aims
To determine the potential of carnosine supplementation for 14 weeks to improve glycaemic
control in type 2 diabetes, reduce risk factors for cardiovascular disease and improve
cognitive function as well as identify metabolic pathways involved, specifically by:
1. Improving glycaemic control (HBA1c, fasting and 2 hour glucose and glucose area under
the curve after oral glucose tolerance test)
2. Reducing cardiovascular risk factors (lipids; arterial (aortic) stiffness; central blood
pressure (cBP); endothelial function).
3. Improve cognitive function (global cognitive score formed by a composite of 4 cognitive
tests)
4. Decrease the chronic low grade inflammation, oxidative stress, advanced glycation end
products, and advanced lipoxidation end products, and increase detoxification of
reactive carbonyl species (RCSs).